首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >-)-Epigallocatechin gallate induced apoptosis in human adrenal cancer NCI-H295 cells through caspase-dependent and caspase-independent pathway.
【24h】

-)-Epigallocatechin gallate induced apoptosis in human adrenal cancer NCI-H295 cells through caspase-dependent and caspase-independent pathway.

机译:-)-表没食子儿茶素没食子酸酯通过胱天蛋白酶依赖性和胱天蛋白酶依赖性途径诱导人肾上腺癌NCI-H295细胞凋亡。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

(-)-Epigallocatechin-3-gallate (EGCG) is a major constituent of green tea and has been identified as an excellent anticancer agent. Nevertheless, there are no reports to date about the molecular mechanisms and signal pathways of EGCG on the induction of apoptosis in human adrenal NCI-H295 cancer cells. The purpose of this study was to investigate the anticancer effect and molecular mechanisms of EGCG on human adrenal NCI-H295 cancer cells. The results showed that EGCG induced growth inhibition in a dose- and time-dependent manner. Moreover, it exerted low cytotoxicity on Detroit 551 normal human embryonic skin cell. When NCI-H295 cells were treated with 20 microM EGCG, the mitochondrial membrane potential decreased and intracellular free Ca(2+) increased in a time-dependent manner as analysed by flow cytometry. EGCG decreased the protein levels of Bcl-2, Bcl-xl, xIAP, cIAP, Hsp70 and Hsp90, but increased the protein expression of Bad, Bax, Fas/CD95, cytochrome c, Apaf-1, AIF, GADD153, GRP78, and caspase-3, -7,-8 and -9 as observed by Western blotting examination. EGCG promoted caspase-8, -9 and -3 activities in a time-dependent manner. However, pretreatment of cells with inhibitors of caspase-8, -9 and -3 led to a decrease in caspase-8, -9 and -3 activities and an increase in the percentage of viable cells. Based on the above findings, it was confirmed that EGCG may be a drug candidate for the treatment of human adrenal cancer in the future.
机译:(-)-表没食子儿茶素-3-没食子酸酯(EGCG)是绿茶的主要成分,已被确认为极好的抗癌剂。然而,迄今为止,还没有关于EGCG在诱导人肾上腺NCI-H295癌细胞凋亡中的分子机制和信号途径的报道。这项研究的目的是研究EGCG对人肾上腺NCI-H295癌细胞的抗癌作用及其分子机制。结果表明,EGCG以剂量和时间依赖性方式诱导生长抑制。此外,它对底特律551正常人胚胎皮肤细胞的细胞毒性较低。当NCI-H295细胞用20 microM EGCG处理时,线粒体膜电位降低,而细胞内游离Ca(2+)则以时间依赖性方式通过流式细胞仪分析。 EGCG降低了Bcl-2,Bcl-xl,xIAP,cIAP,Hsp70和Hsp90的蛋白质水平,但增加了Bad,Bax,Fas / CD95,细胞色素c,Apaf-1,AIF,GADD153,GRP78和通过蛋白质印迹检查观察到的半胱天冬酶-3,-7,-8和-9。 EGCG以时间依赖性方式促进caspase-8,-9和-3活性。但是,用caspase-8,-9和-3抑制剂预处理细胞会导致caspase-8,-9和-3活性降低,而活细胞百分比增加。基于以上发现,证实了EGCG可能是将来治疗人肾上腺癌的候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号